COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CMPS COMPASS Pathways plc

Trading 08-20 10:40:44 EDT

14.00

-0.01

-0.07%

High14.20	Low13.86	Vol509.23K
Open14.00	D1 Closing14.01	Amplitude2.43%
Mkt Cap1.93B	Tradable Cap1.50B	Total Shares138.00M
T/O7.14M	T/O Rate0.48%	Tradable Shares107.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CMPS","market":"US","secType":"STK","nameCN":"COMPASS Pathways plc","latestPrice":14,"timestamp":1787236842122,"preClose":14.01,"halted":0,"volume":509234,"delay":0,"changeRate":-0.0007137758743754309,"floatShares":107000000,"shares":138000000,"eps":-3.611848,"marketStatus":"Trading","change":-0.01,"latestTime":"08-20 10:40:44 EDT","open":14,"high":14.2,"low":13.86,"amount":7138908.670344001,"amplitude":0.024268,"askPrice":14.01,"askSize":113,"bidPrice":13.99,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-3.611848,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787256000000},"marketStatusCode":2,"adr":0,"adrRate":1,"listingDate":1600401600000,"exchange":"NASDAQ","adjPreClose":14.01,"preHourTrading":{"tag":"盘前","latestPrice":13.97,"preClose":14.01,"latestTime":"09:29 EDT","volume":8278,"amount":116346.776764,"timestamp":1787232599999,"change":-0.04,"changeRate":-0.002855,"amplitude":0.022127},"postHourTrading":{"tag":"盘后","latestPrice":14.0293,"preClose":14.01,"latestTime":"19:52 EDT","volume":15380,"amount":215546.9047,"timestamp":1787183547663,"change":0.0193,"changeRate":0.001378,"amplitude":0.019272},"volumeRatio":1.200823,"impliedVol":0.6944,"impliedVolPercentile":0.0478},"requestUrl":"/m/hq/s/CMPS/tweets","defaultTab":"tweets","newsList":[{"id":"2660238944","title":"How COMPASS Pathways’ VA Psilocybin Trial (CMPS) Has Reframed Its Veteran Mental Health Ambitions","url":"https://stock-news.laohu8.com/highlight/detail?id=2660238944","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660238944?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:39","pubTimestamp":1787233192,"startTime":"0","endTime":"0","summary":"Earlier in August 2026, COMPASS Pathways plc announced it is working with the U.S. Department of Veterans Affairs on PIVOT, a multi-site randomized controlled trial testing its COMP360 psilocybin in veterans with treatment-resistant depression, including those with concurrent PTSD, while also presenting at Stifel’s 2026 Biotech Summer Summit in Newport, Rhode Island.\nThe VA collaboration highlights federal interest in evaluating COMP360 within a large veteran population, potentially...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/how-compass-pathways-va-psilocybin-trial-cmps-has-reframed-i","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cmps/compass-pathways/news/how-compass-pathways-va-psilocybin-trial-cmps-has-reframed-i","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659165757","title":"Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659165757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659165757?lang=en_us&edition=fundamental","pubTime":"2026-08-13 23:40","pubTimestamp":1786635611,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS P...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-transmedics-group-tmdx-spyre-therapeutics-syre-and-compass-pathways-cmps-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLV","PSIL","LU0029874061.USD","BK4585","LFSC","CMPS","LU2065731478.USD","TMDX","XBI","BK4139","BK4581","BK4588","LABU","BK4137","HCSG","BK4082","SYRE","LU2324357040.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658939075","title":"COMPASS Pathways (CMPS) Gets a Buy from Evercore ISI","url":"https://stock-news.laohu8.com/highlight/detail?id=2658939075","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658939075?lang=en_us&edition=fundamental","pubTime":"2026-08-10 20:45","pubTimestamp":1786365933,"startTime":"0","endTime":"0","summary":"In a report released today, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on COMPASS Pathways, with a price target of $21.00. Accor...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/compass-pathways-cmps-gets-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/compass-pathways-cmps-gets-a-buy-from-evercore-isi-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657219266","title":"Analysts’ Top Healthcare Picks: COMPASS Pathways (CMPS), Trulieve Cannabis (TRLV)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657219266","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657219266?lang=en_us&edition=fundamental","pubTime":"2026-08-08 06:10","pubTimestamp":1786140605,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on COMPASS Pathways (CMPS) and Trulieve Cannabis (TRLV)...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-compass-pathways-cmps-trulieve-cannabis-trlv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-compass-pathways-cmps-trulieve-cannabis-trlv-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","BK4137","LABU","MSOX","TOKE","TRLV","BK4007","BK4585","BK4139","XLV","MSOS","BK4581","MJ","BK4588","WEED","CMPS","HCSG","XBI","CNBS","LU0128526141.USD","PSIL","YOLO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657651829","title":"Compass Pathways is Maintained at Overweight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657651829","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657651829?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:55","pubTimestamp":1786038900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CMPS/analyst-ratings","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657637864","title":"Compass Pathways price target raised to $22 from $17 at B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2657637864","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657637864?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:38","pubTimestamp":1786023496,"startTime":"0","endTime":"0","summary":"B. Riley analyst Madison El-Saadi raised the firm’s price target on Compass Pathways (CMPS) to $22 from $17 and keeps a Buy rating on the shares po...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/compass-pathways-price-target-raised-to-22-from-17-at-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657631659","title":"RBC Adjusts PT on COMPASS Pathways to $21 From $22, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2657631659","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657631659?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:32","pubTimestamp":1786019564,"startTime":"0","endTime":"0","summary":"COMPASS Pathways (CMPS) has an average rating of buy and mean price target of $23.35, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ba","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMPS","BK4139","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657663689","title":"Ireland's GH Research Q2 Net Loss Widens on Higher R&D Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657663689","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657663689?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:58","pubTimestamp":1786017486,"startTime":"0","endTime":"0","summary":"Ireland's GH Research Q2 net loss widens on higher R&D costsOverviewIreland biopharmaceutical firm's Q2 net loss widened yr/yr, with higher R&D and G&A expensesCompany's cash and marketable securities","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430MD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GHRS","IE00BN0W2W23.USD","BK4533","LU0320765992.SGD","BK4007","LU0889565916.HKD","CNTX","JAZZ","PSIL","LU0823416689.USD","BK4532","BK4539","LU0154245673.USD","BK4139","LU0109394709.USD","IE00BN0W2T93.GBP","CMPS","IE00BN0W2V16.EUR","LU0154245756.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657692633","title":"Scholar Rock Q2 Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2657692633","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657692633?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:22","pubTimestamp":1786015339,"startTime":"0","endTime":"0","summary":"Scholar Rock Q2 net loss narrowsOverviewUS biopharmaceutical firm's Q2 net loss narrowed slightly yr/yr with no revenue recordedOperating expenses for Q2 fell, driven by reduced research and developme","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL1N4430J6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","THNR","CMPS","MNKD","BDTX","BK4139","SRRK","IBRN","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657687402","title":"Compass Pathways Working with U.S. Department of Veterans Affairs for Investigational Study of Psilocybin","url":"https://stock-news.laohu8.com/highlight/detail?id=2657687402","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657687402?lang=en_us&edition=fundamental","pubTime":"2026-08-06 18:42","pubTimestamp":1786012964,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nFWN44318H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CMPS","PSIL","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657571589","title":"Compass Pathways Grants New-Hire Inducement Equity Awards at USD 11.25 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2657571589","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657571589?lang=en_us&edition=fundamental","pubTime":"2026-08-06 05:48","pubTimestamp":1785966539,"startTime":"0","endTime":"0","summary":"Compass Pathways grants new-hire inducement equity awards at USD 11.25 per shareCompass Pathways granted equity awards to 14 newly hired non-executive employees on Aug. 3, 2026 under its 2026 Induceme","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDLbD8XbV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657738605","title":"Compass Pathways Announces New Employee Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657738605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657738605?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:30","pubTimestamp":1785961801,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nTUAMJ72R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657578488","title":"Compass Pathways Plc Files for Mixed Shelf Offering; Size not Disclosed - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657578488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657578488?lang=en_us&edition=fundamental","pubTime":"2026-08-06 04:23","pubTimestamp":1785961439,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nFWN4421TK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PSIL","BK4139","CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657522320","title":"Analysts Offer Insights on Healthcare Companies: COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657522320","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657522320?lang=en_us&edition=fundamental","pubTime":"2026-08-06 02:50","pubTimestamp":1785955808,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on COMPASS Pathways (CMPS), Geron (GERN) and Azenta (AZTA). COMPASS ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-geron-gern-and-azenta-azta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-compass-pathways-cmps-geron-gern-and-azenta-azta-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00B7SZL793.SGD","XBI","IE0031619046.USD","LU0029874061.USD","LU1169589451.USD","GERN","PSIL","AZTA","BK4147","HCSG","LU0012050646.USD","BK4139","BK4121","BK4581","LU0128526141.USD","IE00B66KJ199.SGD","BK4585","BK4588","BK4137","LABU","LU2065732104.USD","LU0106261612.USD","XLV","LU1169590202.USD","CMPS","IE00B19Z4B17.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657540547","title":"Compass Pathways PLC Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657540547","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657540547?lang=en_us&edition=fundamental","pubTime":"2026-08-05 21:32","pubTimestamp":1785936746,"startTime":"0","endTime":"0","summary":"Compass Pathways PLC reports results for the quarter ended June 30 - Earnings SummaryCompass Pathways PLCCMPS.OQreported a quarterly adjusted loss of $1.88 per share for the quarter ended June 30, low","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL8N44224E:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CMPS","PSIL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657544828","title":"Compass Pathways Publishes Investor Presentation on Comp360 Psilocybin Program, FDA Filing Progress and Launch Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2657544828","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657544828?lang=en_us&edition=fundamental","pubTime":"2026-08-05 20:07","pubTimestamp":1785931637,"startTime":"0","endTime":"0","summary":"Compass Pathways publishes investor presentation on COMP360 psilocybin program, FDA filing progress and launch plansCompass Pathways outlined plans to file a rolling NDA for COMP360 psilocybin in trea","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL9WMrTH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657543072","title":"Earnings Flash (CMPS) Compass Pathways Posts Q2 Loss $1.88 a Share, vs. FactSet Est of $0.33 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657543072","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657543072?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:47","pubTimestamp":1785926829,"startTime":"0","endTime":"0","summary":"Earnings Flash (CMPS) Compass Pathways Posts Q2 Loss $1.88 a Share, vs. FactSet Est of $0.33 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CMPS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657545831","title":"Compass Pathways' Q2 Loss Widens on Commercial Readiness Activity Costs","url":"https://stock-news.laohu8.com/highlight/detail?id=2657545831","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657545831?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:45","pubTimestamp":1785926714,"startTime":"0","endTime":"0","summary":"Compass Pathways' Q2 loss widens on commercial readiness activity costsOverviewUK mental health biotech's Q2 operating income missed analyst estimatesNet loss widened yr/yr, mainly due to non-cash war","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nL1N4420FQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211326839.USD","LU2089284900.SGD","LU0310799852.SGD","LU1670710588.SGD","CMPS","LFSC","SG9999013999.USD","LU2065171311.SGD","LU2125154935.USD","LU0266013472.USD","LU1273509221.SGD","LU0526926950.USD","LU1046234339.USD","LU1481600234.SGD","SGXZ57979304.SGD","LU1153585028.USD","LU1585245621.USD","LU0306807586.USD","LU2065170008.USD","LU1718418525.SGD","LU1863844749.USD","LIVN","LU0985481810.HKD","PSIL","LU0203345920.USD","AZN.UK","LU0997586432.USD","LU1057294990.SGD","LU2596442595.SGD","LU0757432116.USD","LU0321505868.SGD","BMY","LU1989772923.USD","03165","LU1196032939.SGD","FTXH","LU1983299246.USD","LU2539964713.USD","LU0575583348.USD","LU0432979614.USD","LU2237443978.SGD","IHE","BK4007","LU1291159041.SGD","LU0096364046.USD","SG9999001176.USD","ACAD","LU0496365809.HKD","LU2279689827.SGD","LU1880407215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657254330","title":"Compass Pathways Q2 EPS $(1.88) Misses $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657254330","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657254330?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:33","pubTimestamp":1785925989,"startTime":"0","endTime":"0","summary":"Compass Pathways (NASDAQ:CMPS) reported quarterly losses of $(1.88) per share which missed the analyst consensus estimate of $(0.37) by 408.11 percent. This is a 358.54 percent decrease over losses of $(0.41) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60941435/compass-pathways-q2-eps-1-88-misses-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PSIL","CMPS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657548774","title":"Compass Pathways Q2 EPS USD -1.88","url":"https://stock-news.laohu8.com/highlight/detail?id=2657548774","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657548774?lang=en_us&edition=fundamental","pubTime":"2026-08-05 18:30","pubTimestamp":1785925800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nPLXD2DKG4:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PSIL","CMPS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.compasspathways.com","stockEarnings":[{"period":"1week","weight":-0.0148},{"period":"1month","weight":0.2005},{"period":"3month","weight":0.2088},{"period":"6month","weight":0.7404},{"period":"1year","weight":2.4254},{"period":"ytd","weight":1.0304}],"compareEarnings":[{"period":"1week","weight":-0.0044},{"period":"1month","weight":0.0363},{"period":"3month","weight":0.0355},{"period":"6month","weight":0.1155},{"period":"1year","weight":0.202},{"period":"ytd","weight":0.1278}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":0.053854},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.067409},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.124725},{"month":4,"riseRate":0.5,"avgChangeRate":0.092687},{"month":5,"riseRate":0.5,"avgChangeRate":0.037097},{"month":6,"riseRate":0.666667,"avgChangeRate":-0.001204},{"month":7,"riseRate":0.666667,"avgChangeRate":0.185901},{"month":8,"riseRate":0.5,"avgChangeRate":0.034233},{"month":9,"riseRate":0.2,"avgChangeRate":-0.10118},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.009194},{"month":11,"riseRate":0.333333,"avgChangeRate":0.034765},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.01163}],"exchange":"NASDAQ","name":"COMPASS Pathways plc","nameEN":"COMPASS Pathways plc","securityTypeName":"DR","adrRate":"1:1"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"COMPASS Pathways plc,CMPS,COMPASS Pathways plc股票,COMPASS Pathways plc股票老虎,COMPASS Pathways plc股票老虎国际,COMPASS Pathways plc行情,COMPASS Pathways plc股票行情,COMPASS Pathways plc股价,COMPASS Pathways plc股市,COMPASS Pathways plc股票价格,COMPASS Pathways plc股票交易,COMPASS Pathways plc股票购买,COMPASS Pathways plc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"COMPASS Pathways plc(CMPS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest COMPASS Pathways plc(CMPS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction